NCI-60 Cancer Cell Lines View all Bright Field applications →
Introduction to NCI-60 Human Cancer Cell Lines
The late 1980s saw the development and creation of the National Cancer Institute (NCI) 60 human tumor cell line anticancer drug discovery project. This project was intended to screen thousands of pharmacological compounds for anticancer activity, thus replacing earlier cumbersome en vivo models. The 60 created cell lines represent nine human cancers: breast, central nervous system, colon, kidney, leukemia, lung, melanoma, ovary, and prostate. Since its inception, the testing of anticancer drugs using the NCI-60 panel has generated the most extensive cancer pharmacology database in the world.3 It has also provided invaluable knowledge in genome mutations, drug – tumor interactions and general tumor biology.
Nexcelom performed Cellometer image cytometry on all NCI-60 cancer cell lines. Every cell sample was individually stained with trypan blue, imaged and analyzed using the Cellometer Auto T4. Each sample was assessed for viability and cell size. The ability to accurately measure cell viability and cell size are two important components in determining the functionality of anticancer compounds. Cell death, or reduced cell size in certain tumor cell lines could be an indicator of compound efficacy.
NCI-60 Human Cancer Cell Lines
Using the Cellometer Auto T4, we imaged and counted every NCI-60 cancer cell line, obtaining the cell concentration, viability, and cell size. Shown here, are the enlarged representative images of each cell line. Since all of the cells were stained with trypan blue, we show the stained trypan blue image as well as the Cellometer counted image.
The cells are organized alphabetically by the organ or origin.
Download Excel Table: Cell size distribution for all 60 NCI cancer cell lines
NCI-60 Breast Cell Lines
Shown below are stained trypan blue images and Cellometer counted images of NCI-60 breast cell lines. Counted live cells are outlined in green while the dead trypan blue positive cells are outlined in red.
BT-549 cells

Hs 578T

MCF7

MDA-MB-231

MDA-MB-468

T-47D

NCI-60 Central Nervous System Cell Lines
Shown below are stained trypan blue images and Cellometer counted images of NCI-60 central nervous system cell lines. Counted live cells are outlined in green while the dead trypan blue positive cells are outlined in red.
SF-268

SF-295

SF-539

SNB-19

SNB-75

U251

NCI-60 Colon Cell Lines
Shown below are stained trypan blue images and Cellometer counted images of NCI-60 colon cell lines. Counted live cells are outlined in green while the dead trypan blue positive cells are outlined in red.
Colo205

HCC-2998

HCT-116

HCT-15

HT29

KM12

SW-620

NCI-60 Kidney Cell Lines
Shown below are stained trypan blue images and Cellometer counted images of NCI-60 kidney cell lines. Counted live cells are outlined in green while the dead trypan blue positive cells are outlined in red.
786-O

A498

ACHN

CAKI-1

RXF 393

SN12C

TK-10

UO-31

NCI-60 Leukemia Cell Lines
Shown below are stained trypan blue images and Cellometer counted images of NCI-60 leukemia cell lines.. Counted live cells are outlined in green while the dead trypan blue positive cells are outlined in red.
CCRF-CEM

HL-60

K-562

MOLT-4

RPMI-8226

SR

NCI-60 Lung Cell Lines
Shown below are stained trypan blue images and Cellometer counted images of NCI-60 lung cell lines. Counted live cells are outlined in green while the dead trypan blue positive cells are outlined in red.
A549

EKVX

HOP-62

HOP-92

NCI-H226

NCI-H23

NCI-H322M

NCI-H460

NCI-H522

NCI-60 Melanoma Cell Lines
Shown below are stained trypan blue images and Cellometer counted images of NCI-60 melanoma cell lines. Counted live cells are outlined in green while the dead trypan blue positive cells are outlined in red.
LOX-IMVI

M14

MALME-3M

MDA-MB-435

SK-MEL-2

SK-MEL-28

SK-MEL-5

UACC-257

UACC-62

NCI-60 Ovarian Cell Lines
Shown below are stained trypan blue images and Cellometer counted images of NCI-60 ovarian cell lines. Counted live cells are outlined in green while the dead trypan blue positive cells are outlined in red.
IGROV1

NCI/ADR-RES

OVCAR-3

OVCAR-4

OVCAR-5

OVCAR-8

SK-OV-3

NCI-60 Prostate Cell Lines
Shown below are stained trypan blue images and Cellometer counted images of NCI-60 prostate cell lines. Counted live cells are outlined in green while the dead trypan blue positive cells are outlined in red.
DU-145

PC-3

List and Description of NCI-60 Cancer Cell Lines
Name
Species
Organ of Origin
Doubling Time (Hrs)
Disease
Culture
BT549
Human
Breast
53.9
Ductal Carcinoma
Adherent
HS 578T
Human
Breast
53.8
Carcinoma
Adherent
MCF7
Human
Breast
25.4
Adenocarcinoma
Adherent
MDA-MB-231
Human
Breast
41.9
Adenocarcinoma
Adherent
MDA-MB-468
Human
Breast
62
Adenocarcinoma
Adherent
T-47D
Human
Breast
45.5
Ductal Carcinoma
Adherent
SF268
Human
CNS
33.1
Anaplastic Astrocytoma
Adherent
SF295
Human
CNS
29.5
Glioblastoma-Multiforme
Adherent
SF539
Human
CNS
35.4
Glioblastoma
Adherent
SNB-19
Human
CNS
34.6
Glioblastoma
Adherent
SNB-75
Human
CNS
62.8
Astrocytoma
Adherent
U251
Human
CNS
23.8
Glioblastoma
Adherent
Colo205
Human
Colon
23.8
Dukes' type D, Colorectal
adenocarcinoma
Adherent & Suspension
HCC 2998
Human
Colon
31.5
Carcinoma
Adherent
HCT-116
Human
Colon
17.4
Carcinoma
Adherent
HCT-15
Human
Colon
20.6
Dukes' type C, Colorectal
adenocarcinoma
Adherent
HT29
Human
Colon
19.5
Colorectal adenocarcinoma
Adherent
KM12
Human
Colon
23.7
Adenocarcinoma, Grade III
Adherent
SW620
Human
Colon
20.4
Adenocarcinoma
Adherent
786-O
Human
Kidney
22.4
renal cell adenocarcinoma
Adherent
A498
Human
Kidney
66.8
Adenocarcinoma
Adherent
ACHN
Human
Kidney
27.5
renal cell adenocarcinoma
Adherent
CAKI
Human
Kidney
39
clear cell carcinoma
Adherent
RXF 393
Human
Kidney
62.9
Poorly Differentiated
Hypernephroma
Adherent
SN12C
Human
Kidney
29.5
Carcinoma
Adherent
TK-10
Human
Kidney
51.3
Spindle Cell carcinoma
Adherent
UO-31
Human
Kidney
41.7
Carcinoma
Adherent
CCRF-CEM
Human
Leukemia
26.7
acute lymphoblastic leukemia
Suspension
HL-60
Human
Leukemia
28.6
acute promyelocytic leukemia
Suspension
K562
Human
Leukemia
19.6
chronic myelogenous leukemia
Suspension
MOLT-4
Human
Leukemia
27.9
acute lymphoblastic leukemia
Suspension
RPMI-8226
Human
Leukemia
33.5
plasmacytoma, myeloma
Suspension
SR
Human
Leukemia
28.7
Large Cell, Immunoblastic
Suspension
A549
Human
Lung
22.9
Adenocarcinoma
Adherent
EKVX
Human
Lung
43.6
Adenocarcinoma
Adherent
HOP-62
Human
Lung
39
Adenocarcinoma
Adherent
HOP-92
Human
Lung
79.5
Large Cell, Undifferentiated
Adherent & Suspension
NCI-H226
Human
Lung
61
squamous cell carcinoma;
mesothelioma
Adherent
NCI-H23
Human
Lung
33.4
adenocarcinoma; non-small
cell lung cancer
Adherent
NCI-H322M
Human
Lung
35.3
Small Cell Bronchioalveolar
Carcinoma
Suspension
NCI-H460
Human
Lung
17.8
carcinoma; large cell lung cancer
Adherent
NCI-H522
Human
Lung
38.2
adenocarcinoma; non-small
cell lung cancer
Adherent
LOX IMVI
Human
Melanoma
20.5
Malignant Amelanotic melanoma
Semi-Adherent
M14
Human
Melanoma
26.3
malignant melanoma
Adherent
MALME-3M
Human
Melanoma
46.2
malignant melanoma
Adherent & Suspension
MDA-MB-435
Human
Melanoma
25.8
Adenocarcinoma
Adherent
SK-MEL-2
Human
Melanoma
45.5
malignant melanoma
Adherent
SK-MEL-28
Human
Melanoma
35.1
malignant melanoma
Adherent
SK-MEL-5
Human
Melanoma
25.2
malignant melanoma
Adherent
UACC-257
Human
Melanoma
38.5
malignant melanoma
Adherent
UACC-62
Human
Melanoma
31.3
malignant melanoma
Adherent
IGROV1
Human
Ovary
31
Cystoadenocarcinoma
Adherent
OVCAR-3
Human
Ovary
34.7
Adenocarcinoma
Adherent
OVCAR-4
Human
Ovary
41.4
Adenocarcinoma
Adherent
OVCAR-5
Human
Ovary
48.8
Adenocarcinoma
Adherent
OVCAR-8
Human
Ovary
26.1
Adenocarcinoma
Adherent
SK-OV-3
Human
Ovary
48.7
Adenocarcinoma
Adherent
NCI-ADR-RES
Human
Ovary
34
Adenocarcinoma
Adherent
DU145
Human
Prostate
32.3
Carcinoma
Adherent
PC-3
Human
Prostate
27.1
grade IV, adenocarcinoma
Adherent
Compiled data from multiple sources 1, 2, 3
Download the full NCI-60 cancer cell line data list, which includes the cell size measurements of all 60 cell lines.
Conclusions
The Cellometer line of instruments is capable of measuring the cell concentration, viability, and cell size of all 60 NCI cancer cell lines. The innovative "Accurate Cell Membrane Outline Algorithm" assures that all cell samples are de-clustered and counted properly. The ability of the Cellometer instruments to accurately and consistently measure cell concentration, viability, and cell size provides researchers with a reliable tool in their cancer research.
Publications Using Cellometer Counting for NCI-60 Cancer Cell Lines
- Tedeschi PM, Markert EK, Gounder M, et al. (2013) Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death & Disease 4:e877.
- Dolfi SC, Chan LL, Qiu J, et al. (2013) The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer & Metabolism 1(1):20.
Additional Citations
- Jerry M. Collins, Developmental Therapeutics Program NCI/NIH. http://dtp.nci.nih.gov/
- DTP, DCTD Tumor Repository. A Catalog of in Vitro Cell Lines, Transplantable Animal and Human Tumors and Yeast. The Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute. 2013
- Abaan OD, Polley EC, Davis SR, et al. (2013) The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Research.
Name | Species | Organ of Origin | Doubling Time (Hrs) | Disease | Culture |
---|---|---|---|---|---|
BT549 | Human | Breast | 53.9 | Ductal Carcinoma | Adherent |
HS 578T | Human | Breast | 53.8 | Carcinoma | Adherent |
MCF7 | Human | Breast | 25.4 | Adenocarcinoma | Adherent |
MDA-MB-231 | Human | Breast | 41.9 | Adenocarcinoma | Adherent |
MDA-MB-468 | Human | Breast | 62 | Adenocarcinoma | Adherent |
T-47D | Human | Breast | 45.5 | Ductal Carcinoma | Adherent |
SF268 | Human | CNS | 33.1 | Anaplastic Astrocytoma | Adherent |
SF295 | Human | CNS | 29.5 | Glioblastoma-Multiforme | Adherent |
SF539 | Human | CNS | 35.4 | Glioblastoma | Adherent |
SNB-19 | Human | CNS | 34.6 | Glioblastoma | Adherent |
SNB-75 | Human | CNS | 62.8 | Astrocytoma | Adherent |
U251 | Human | CNS | 23.8 | Glioblastoma | Adherent |
Colo205 | Human | Colon | 23.8 | Dukes' type D, Colorectal adenocarcinoma | Adherent & Suspension |
HCC 2998 | Human | Colon | 31.5 | Carcinoma | Adherent |
HCT-116 | Human | Colon | 17.4 | Carcinoma | Adherent |
HCT-15 | Human | Colon | 20.6 | Dukes' type C, Colorectal adenocarcinoma | Adherent |
HT29 | Human | Colon | 19.5 | Colorectal adenocarcinoma | Adherent |
KM12 | Human | Colon | 23.7 | Adenocarcinoma, Grade III | Adherent |
SW620 | Human | Colon | 20.4 | Adenocarcinoma | Adherent |
786-O | Human | Kidney | 22.4 | renal cell adenocarcinoma | Adherent |
A498 | Human | Kidney | 66.8 | Adenocarcinoma | Adherent |
ACHN | Human | Kidney | 27.5 | renal cell adenocarcinoma | Adherent |
CAKI | Human | Kidney | 39 | clear cell carcinoma | Adherent |
RXF 393 | Human | Kidney | 62.9 | Poorly Differentiated Hypernephroma | Adherent |
SN12C | Human | Kidney | 29.5 | Carcinoma | Adherent |
TK-10 | Human | Kidney | 51.3 | Spindle Cell carcinoma | Adherent |
UO-31 | Human | Kidney | 41.7 | Carcinoma | Adherent |
CCRF-CEM | Human | Leukemia | 26.7 | acute lymphoblastic leukemia | Suspension |
HL-60 | Human | Leukemia | 28.6 | acute promyelocytic leukemia | Suspension |
K562 | Human | Leukemia | 19.6 | chronic myelogenous leukemia | Suspension |
MOLT-4 | Human | Leukemia | 27.9 | acute lymphoblastic leukemia | Suspension |
RPMI-8226 | Human | Leukemia | 33.5 | plasmacytoma, myeloma | Suspension |
SR | Human | Leukemia | 28.7 | Large Cell, Immunoblastic | Suspension |
A549 | Human | Lung | 22.9 | Adenocarcinoma | Adherent |
EKVX | Human | Lung | 43.6 | Adenocarcinoma | Adherent |
HOP-62 | Human | Lung | 39 | Adenocarcinoma | Adherent |
HOP-92 | Human | Lung | 79.5 | Large Cell, Undifferentiated | Adherent & Suspension |
NCI-H226 | Human | Lung | 61 | squamous cell carcinoma; mesothelioma | Adherent |
NCI-H23 | Human | Lung | 33.4 | adenocarcinoma; non-small cell lung cancer | Adherent |
NCI-H322M | Human | Lung | 35.3 | Small Cell Bronchioalveolar Carcinoma | Suspension |
NCI-H460 | Human | Lung | 17.8 | carcinoma; large cell lung cancer | Adherent |
NCI-H522 | Human | Lung | 38.2 | adenocarcinoma; non-small cell lung cancer | Adherent |
LOX IMVI | Human | Melanoma | 20.5 | Malignant Amelanotic melanoma | Semi-Adherent |
M14 | Human | Melanoma | 26.3 | malignant melanoma | Adherent |
MALME-3M | Human | Melanoma | 46.2 | malignant melanoma | Adherent & Suspension |
MDA-MB-435 | Human | Melanoma | 25.8 | Adenocarcinoma | Adherent |
SK-MEL-2 | Human | Melanoma | 45.5 | malignant melanoma | Adherent |
SK-MEL-28 | Human | Melanoma | 35.1 | malignant melanoma | Adherent |
SK-MEL-5 | Human | Melanoma | 25.2 | malignant melanoma | Adherent |
UACC-257 | Human | Melanoma | 38.5 | malignant melanoma | Adherent |
UACC-62 | Human | Melanoma | 31.3 | malignant melanoma | Adherent |
IGROV1 | Human | Ovary | 31 | Cystoadenocarcinoma | Adherent |
OVCAR-3 | Human | Ovary | 34.7 | Adenocarcinoma | Adherent |
OVCAR-4 | Human | Ovary | 41.4 | Adenocarcinoma | Adherent |
OVCAR-5 | Human | Ovary | 48.8 | Adenocarcinoma | Adherent |
OVCAR-8 | Human | Ovary | 26.1 | Adenocarcinoma | Adherent |
SK-OV-3 | Human | Ovary | 48.7 | Adenocarcinoma | Adherent |
NCI-ADR-RES | Human | Ovary | 34 | Adenocarcinoma | Adherent |
DU145 | Human | Prostate | 32.3 | Carcinoma | Adherent |
PC-3 | Human | Prostate | 27.1 | grade IV, adenocarcinoma | Adherent |
Compiled data from multiple sources 1, 2, 3
Download the full NCI-60 cancer cell line data list, which includes the cell size measurements of all 60 cell lines.
The Cellometer line of instruments is capable of measuring the cell concentration, viability, and cell size of all 60 NCI cancer cell lines. The innovative "Accurate Cell Membrane Outline Algorithm" assures that all cell samples are de-clustered and counted properly. The ability of the Cellometer instruments to accurately and consistently measure cell concentration, viability, and cell size provides researchers with a reliable tool in their cancer research.
- Tedeschi PM, Markert EK, Gounder M, et al. (2013) Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death & Disease 4:e877.
- Dolfi SC, Chan LL, Qiu J, et al. (2013) The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer & Metabolism 1(1):20.
- Jerry M. Collins, Developmental Therapeutics Program NCI/NIH. http://dtp.nci.nih.gov/
- DTP, DCTD Tumor Repository. A Catalog of in Vitro Cell Lines, Transplantable Animal and Human Tumors and Yeast. The Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute. 2013
- Abaan OD, Polley EC, Davis SR, et al. (2013) The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Research.